Ductal Carcinoma in Situ (DCIS): Symptoms, Diagnosis, Treatment and Cost in India

Ductal carcinoma in situ, or DCIS, is often discovered during a mammogram before a woman notices any breast symptoms. It is sometimes described as stage 0 breast cancer or non-invasive breast cancer. The important point is that the abnormal cells are still confined to the milk ducts and have not invaded the surrounding breast tissue.

That makes DCIS very different from invasive breast cancer. At the same time, doctors generally take DCIS seriously because some DCIS can progress to invasive breast cancer if it is left untreated, and currently it is not possible to predict with complete certainty which individual lesions will progress. Treatment therefore has to balance two things: removing or controlling the abnormal cells while avoiding more treatment than a particular patient actually needs.

For someone diagnosed with DCIS in India, understanding the pathology report is especially important. The size, grade, extent of DCIS, surgical margins, hormone-receptor status and the distribution of the abnormal area can all influence the treatment discussion. This guide supports the Breast Cancer Treatment in India pathway and the diagnosis explainer.

The breast contains a network of milk ducts. These ducts carry milk toward the nipple. In DCIS, abnormal cells develop within the lining of these ducts. The cells have not broken through the duct wall into the surrounding breast tissue. That distinction is what makes DCIS non-invasive. Once cancer cells break through the duct wall and invade nearby breast tissue, the diagnosis changes to invasive breast cancer. So, DCIS is not the same thing as invasive ductal carcinoma.

DCIS is commonly referred to as stage 0 breast cancer. Stage 0 means that abnormal cells have been found at their original site without evidence that they have invaded surrounding breast tissue. This is different from stages I through IV, which are used for invasive breast cancer. It is worth remembering that "stage 0" does not mean that the finding should simply be ignored. It means the disease has been identified before invasion has occurred. See breast cancer stages.

DCIS itself has not invaded surrounding tissue or spread to distant organs. The concern is what may happen if some DCIS progresses and becomes invasive. Researchers are still studying why some lesions progress while others may never become invasive. The National Cancer Institute notes that there is currently no reliable way to determine with certainty which individual DCIS lesions will progress to invasive disease. This uncertainty is one reason treatment recommendations can sometimes be difficult to understand.

Most people with DCIS do not have obvious symptoms. It is frequently discovered during routine breast screening, particularly when a mammogram shows an area of abnormal calcification. Occasionally a person may notice a breast lump, nipple discharge, a change in the nipple or a localized breast change. These symptoms are not specific to DCIS.

DCIS can produce tiny deposits of calcium called microcalcifications. These may be visible on a mammogram even when the breast feels completely normal. This is one reason screening mammography can detect breast abnormalities before they become clinically obvious. According to NCI's physician information, more than 90% of DCIS cases are diagnosed by mammography alone in the cited screening context.

An abnormal mammogram does not automatically mean DCIS. Additional evaluation may include diagnostic mammography, breast ultrasound, further breast imaging when appropriate and an image-guided biopsy. The biopsy is what establishes the diagnosis. A radiologist may use stereotactic guidance, ultrasound guidance or another appropriate technique depending on where the abnormality is located. See diagnosis tests.

Imaging can identify an area that looks abnormal. It cannot reliably tell whether that area contains DCIS, another type of breast lesion or an invasive cancer. A biopsy removes tissue for examination by a pathologist. The pathology report can then establish whether abnormal cells are confined to the ducts and provide important information about the DCIS.

Receiving a pathology report can be overwhelming because it contains medical terminology that may not be familiar. Several parts are particularly important: grade, size or extent, distribution, hormone-receptor status and, after surgery, surgical margins. See the pathology report explainer.

DCIS is commonly classified as low grade, intermediate grade or high grade. The grade describes how abnormal the cells look under the microscope and provides information about how quickly the cells are behaving. High-grade DCIS generally has more abnormal cellular features and is associated with a higher risk of recurrence and progression than low-grade disease.

You may see the term comedo necrosis or comedo-type DCIS in a pathology report. This refers to dead or necrotic material within the involved ducts. Comedo-type DCIS is generally associated with higher-grade disease and a greater likelihood of associated invasive cancer than some other patterns. However, one word on a pathology report should not be interpreted in isolation. Your breast specialist should consider the entire pathology report.

The area of DCIS can influence treatment planning. A small localized area may be suitable for breast-conserving surgery. A larger area may make breast conservation technically difficult, particularly if removing the entire area would leave an unacceptable breast shape. The distribution also matters. DCIS found in several separate areas of the breast may lead the surgeon to recommend mastectomy rather than lumpectomy.

A surgical margin is the edge of the tissue removed during surgery. After lumpectomy, the pathologist examines the edges of the specimen. The goal is to determine whether DCIS extends to the margin. If DCIS is present at or too close to the margin according to the treating team's criteria, additional surgery may be recommended. This can sometimes mean another lumpectomy. In other situations, mastectomy may be considered.

The main treatment options include lumpectomy, lumpectomy followed by radiation in appropriate patients, mastectomy, and hormone therapy for selected hormone-receptor-positive DCIS. The appropriate approach depends on the extent and characteristics of the disease.

Lumpectomy is also called breast-conserving surgery. The surgeon removes the DCIS along with a surrounding margin of normal breast tissue while preserving most of the breast. It may be appropriate when the DCIS is localized and can be removed while leaving an acceptable amount of healthy breast tissue. The removed tissue is sent to pathology. The pathology report then confirms whether the DCIS has been completely removed and whether there is any unexpected invasive cancer.

Radiation is commonly recommended after breast-conserving surgery for DCIS. Its purpose is to reduce the risk of the disease returning in the treated breast, either as DCIS or invasive breast cancer. However, radiation is not necessarily appropriate for every person. Some carefully selected patients with lower-risk disease may discuss omission of radiation with their doctors. The decision depends on factors such as age, grade, size, margins and other features. See radiation therapy and radiation side effects.

In selected circumstances, it may be considered. For example, some older patients or people with significant health problems may discuss avoiding radiation. There is also ongoing research into whether carefully selected patients with low-risk DCIS can be safely managed with less intensive treatment. NCI notes that active surveillance is an area of ongoing research, and longer-term evidence is still needed before it can be considered appropriate for everyone with low-risk DCIS. This is an important distinction. Active surveillance is not currently a universal replacement for surgery.

Mastectomy removes the entire breast containing the DCIS. It may be considered when the DCIS covers a large portion of the breast, DCIS is present in multiple separate areas, clear margins cannot be achieved with breast-conserving surgery, or the breast would be significantly distorted by removing the affected area. These decisions are individualized. Reconstruction can be discussed at the same time; see reconstruction after mastectomy.

Mastectomy removes the breast containing the DCIS and provides very strong local control. NCI reports that people with DCIS generally have an excellent prognosis, with more than 98% alive five years after diagnosis in the cited population. However, no cancer treatment should be described as a guarantee. The final pathology matters because an invasive cancer can occasionally be found in the surgical specimen even when the initial biopsy showed DCIS.

Usually, lymph-node surgery is not necessary for a straightforward lumpectomy for DCIS. However, sentinel lymph node biopsy may be performed during mastectomy because if invasive cancer is unexpectedly found afterward, performing the sentinel node procedure later may not be feasible in the same way. The decision should be made before surgery.

Yes. Sometimes the initial needle biopsy samples only part of the abnormal area. A larger surgical specimen may subsequently show an invasive component that was not captured in the original biopsy. This is one reason the final surgical pathology report can be important in determining whether the treatment plan needs to change.

For pure DCIS, chemotherapy is generally not part of standard treatment. The reason is straightforward: the abnormal cells have not invaded the surrounding tissue. If invasive breast cancer is identified in the surgical specimen, however, the situation changes. The treatment team would then assess the invasive cancer according to its stage, ER, PR, HER2 status and other relevant factors. See ER, PR and HER2.

It can be. If DCIS is hormone receptor-positive, hormone therapy may be discussed after surgery. Tamoxifen is one option. For some postmenopausal women, an aromatase inhibitor may also be considered. Hormone therapy in DCIS is primarily used to reduce the risk of another DCIS or invasive breast cancer. It is not the same treatment approach used for advanced hormone receptor-positive invasive breast cancer. See hormone therapy and side effects.

ER and PR testing can help guide treatment decisions. HER2 is different. NCI notes that HER2 is generally not routinely tested in DCIS in the same way it is for invasive breast cancer. If invasive cancer is identified, however, HER2 testing becomes relevant to the treatment decision.

This is an area of active research. Some clinical trials are examining whether carefully selected low-risk DCIS can be monitored rather than immediately treated with surgery. However, there is still uncertainty about which individual lesions will progress. NCI notes that longer follow-up is needed to determine whether active monitoring can safely replace surgery for selected patients. Therefore, a patient should not assume that a diagnosis of "low-grade DCIS" automatically means observation is appropriate.

There is no single treatment that is right for every person with DCIS. Your breast cancer team may consider the size of the DCIS, location, number of areas involved, grade, presence of necrosis, surgical margins, breast size and shape, age, other medical conditions, hormone-receptor status, personal preferences, ability to undergo radiation and previous radiation treatment. This is why two people with DCIS can receive different treatment plans.

India has breast cancer centres that can provide the complete diagnostic and treatment pathway for DCIS. A typical team may include a breast surgeon, surgical oncologist, breast radiologist, pathologist, radiation oncologist, medical oncologist when required and a reconstructive surgeon when appropriate. For a straightforward DCIS diagnosis, the treatment may be much less extensive than the treatment required for invasive breast cancer. That is why obtaining the pathology and imaging before deciding on treatment is important. Teams in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad can review slides and imaging before confirming surgery.

Pathology determines whether the abnormal cells are truly confined to the ducts. It also determines grade and other characteristics that influence treatment. For an international patient considering treatment in India, the hospital may review original biopsy slides, tissue blocks, the pathology report, mammograms, ultrasound, MRI and previous medical records. A second pathology review can be particularly useful when the diagnosis or grade is unclear or when treatment recommendations differ between doctors. See the international-patient guide.

If you are traveling to India after a DCIS diagnosis, try to bring the original biopsy report, pathology slides if available, tissue blocks if available, mammography images, ultrasound images, MRI images if performed, previous consultation notes, a medication list, previous breast surgery records and family history information. Digital copies are useful, but the hospital may request original pathology material for review. Hospitals in Delhi NCR and Mumbai can arrange pathology review before the first operation.

The cost of treating DCIS varies considerably. A patient undergoing a small lumpectomy has a very different treatment pathway from someone requiring mastectomy and reconstruction. Potential expenses include diagnostic imaging, breast biopsy, pathology review, surgery, hospitalization, radiation therapy, hormone therapy, additional surgery if margins are not clear, reconstruction where appropriate and follow-up consultations. For this reason, a generic "DCIS treatment package" can be misleading. The appropriate estimate should be based on the patient's pathology and proposed treatment plan. See the cost guide.

Breast-conserving surgery doctors · cost · mastectomy doctors · cost · reconstruction doctors · cost · hormone therapy · cost.

Lumpectomy is generally less extensive than mastectomy. Recovery depends on the size and location of the excision, the surgical technique, whether lymph-node surgery was performed, individual healing and whether additional surgery is required. Some patients return to normal activities relatively quickly. However, the breast may remain swollen or bruised for some time. Radiation, if recommended, begins after the surgical wound has healed sufficiently.

Recovery from mastectomy generally takes longer than recovery from a small lumpectomy. If reconstruction is performed at the same time, recovery may be different again. Patients may need wound care, drain management, pain medication, activity restrictions, follow-up appointments and physiotherapy when indicated. The surgical team should provide specific instructions before discharge.

Follow-up remains important. Depending on the treatment, your doctor may monitor the treated breast, the opposite breast, surgical scars, new breast symptoms, hormone therapy side effects and imaging results. If you had breast-conserving surgery, surveillance of the remaining breast tissue is particularly important. The follow-up schedule should be individualized. See follow-up tests.

Yes. DCIS can recur in the treated breast after breast-conserving treatment. A recurrence may be DCIS again or may be invasive breast cancer. The risk depends on factors such as the original DCIS characteristics and treatment. Radiation after lumpectomy reduces the risk of recurrence in the treated breast. Mastectomy has a very low local recurrence risk, although ongoing follow-up remains appropriate.

It can. A diagnosis of DCIS in one breast does not mean the other breast is automatically affected. However, people who have had DCIS remain at risk of developing another breast cancer. Hormone therapy may be recommended in selected hormone receptor-positive cases partly because it can lower the risk of developing another DCIS or invasive breast cancer.

DCIS has an excellent prognosis. The NCI reports that more than 98% of people diagnosed with DCIS are alive five years after diagnosis in the cited population. Individual outcomes can differ, and population statistics cannot predict what will happen to one particular patient. The key point is that DCIS is generally identified before invasive spread has occurred.

GAF Healthcare can help an international patient send biopsy slides, mammograms and the pathology report for review before travel, then coordinate a breast surgeon, pathologist and radiation oncologist in India. The useful output is a written plan: whether lumpectomy is feasible, whether radiation is likely, and what the case-specific estimate includes.

DCIS is classified as a non-invasive or pre-invasive breast cancer and is also called stage 0 breast cancer. The abnormal cells remain inside the milk ducts.

It should be evaluated and treated according to its characteristics because some DCIS can progress to invasive cancer. However, DCIS has an excellent overall prognosis.

Pure DCIS has not invaded beyond the ducts, so it does not behave like invasive breast cancer. If invasive cancer is found alongside DCIS, lymph-node evaluation becomes more relevant.

Chemotherapy is generally not used for pure DCIS. If invasive cancer is discovered, treatment is reconsidered according to the invasive cancer's characteristics.

Radiation is commonly recommended after lumpectomy, but selected patients may discuss omission with their doctors based on individual risk factors.

No. Many patients can undergo breast-conserving surgery. Mastectomy may be recommended when DCIS is extensive, multicentric or cannot be removed with satisfactory margins.

DCIS has an excellent prognosis, and most people can be successfully treated. The NCI reports more than 98% five-year relative survival in the cited population.

Yes. Some DCIS can progress to invasive disease, although doctors cannot currently predict with certainty which individual lesions will do so.

It may be considered when the DCIS is hormone receptor-positive. Tamoxifen and, for some postmenopausal women, aromatase inhibitors may be options.

Yes. Diagnosis and treatment can be provided through multidisciplinary breast cancer centers in India.

There is no universal cost. The amount depends on the surgery, pathology, radiation, medication and other treatment requirements.

DCIS is an important breast abnormality because it is detected before cancer cells have invaded the surrounding breast tissue. For many women, the diagnosis comes unexpectedly after a routine mammogram. The next step is not to assume that every DCIS requires the same treatment. The pathology report matters. The grade, size, distribution, margins and hormone-receptor status, along with the patient's age, health and preferences, help the treatment team decide between breast-conserving surgery, mastectomy, radiation and hormone therapy.

Research is also examining whether carefully selected low-risk DCIS can be monitored instead of immediately treated, but this remains an evolving area and is not appropriate for everyone. For patients coming to India, obtaining a review of the biopsy, imaging and pathology before finalizing treatment can make the consultation much more productive. Most importantly, DCIS is not the same as invasive breast cancer. It is a diagnosis that gives doctors an opportunity to intervene while the abnormal cells remain confined to the milk ducts.

• Breast Cancer Treatment in India
• Pathology report · diagnosis · stages
• Surgery · lumpectomy vs mastectomy · reconstruction
• Radiation · hormone therapy
• Breast-conserving surgery doctors
• Mastectomy doctors · reconstruction doctors
• International patients · cost guide